Nathalie Støer



Nathalie is working as a statistician in the research department advising on study design and statistical analyses, in addition to analyze data in a number of projects. She is also interested in phamacoepidemiology and is involved in various projects about medication use, among others menopausal hormone therapy, and cancer risk. Other projects investigates if commonly used drugs used in addition to standard-of-care treatment can improve cancer prognosis.

From before Nathalie has experience in epidemiological sampling designs and how to utilize the sampled information in the best possible way.


Nathalie has a PhD in biostatistics from University of Oslo. Before she came to the cancer registry in 2016 she was a postdoc at Karolinska Institutet



Kartlegging av legemidler og kreft

Kreftrisiko og overlevelse ved medikamentbruk

Vitamin-D, leptin, overvekt og føflekkreft

Innovativ satsing på tiltak mot kreft (iPAAC)

Forskning på miljøgifter og kreft


Selected publications:

Botteri EStøer NCWeiderpass E, Pukkala E, Ylikorkala O, Lyytinen H (2019)
Menopausal Hormone Therapy and Risk of Melanoma: A Nationwide Register-Based Study in Finland
Cancer Epidemiol Biomarkers Prev, 28 (11), 1857-1860
DOI 10.1158/1055-9965.EPI-19-0554, PubMed 31455672

Støer NCBotteri E, Ghiasvand R, Busund M, Vangen S, Lund E, Veierød MB, Weiderpass E (2019)
Reproductive factors and risk of melanoma: a population-based cohort study
Br J Dermatol, 181 (2), 282-289
DOI 10.1111/bjd.17771, PubMed 30748007

Andreassen BKStøer NCMartinsen JIUrsin GWeiderpass E, Thoresen GH, Debernard KB, Karlstad Ø, Pottegard A, Friis S (2019)
Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry-based study
BMJ Open, 9 (4), e028504
DOI 10.1136/bmjopen-2018-028504, PubMed 30962244

Botteri EStøer NC, Sakshaug S, Graff-Iversen S, Vangen SHofvind SUrsin GWeiderpass E (2017)
Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
Int J Cancer, 141 (9), 1763-1770
DOI 10.1002/ijc.30878, PubMed 28685818